ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives $4.60 Consensus Target Price from Analysts

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the six research firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $4.60.

Separately, Weiss Ratings lowered ALX Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, September 2nd.

Get ALX Oncology alerts:

Check Out Our Latest Stock Analysis on ALXO

Institutional Trading of ALX Oncology

Several large investors have recently bought and sold shares of ALXO. Beacon Pointe Advisors LLC acquired a new position in ALX Oncology during the 2nd quarter valued at approximately $26,000. Callan Family Office LLC purchased a new stake in shares of ALX Oncology during the second quarter valued at $46,000. Invesco Ltd. acquired a new position in shares of ALX Oncology in the 1st quarter valued at $46,000. The Manufacturers Life Insurance Company acquired a new position in shares of ALX Oncology in the 2nd quarter valued at $64,000. Finally, Bridgeway Capital Management LLC purchased a new position in ALX Oncology in the 3rd quarter worth $66,000. Hedge funds and other institutional investors own 97.97% of the company’s stock.

ALX Oncology Stock Up 2.1%

Shares of ALX Oncology stock opened at $1.94 on Wednesday. ALX Oncology has a 52-week low of $1.01 and a 52-week high of $2.66. The firm’s 50 day moving average price is $2.02 and its 200-day moving average price is $1.94. The company has a quick ratio of 9.71, a current ratio of 9.71 and a debt-to-equity ratio of 0.07. The company has a market cap of $268.26 million, a P/E ratio of -1.72 and a beta of 0.39.

ALX Oncology (NASDAQ:ALXO – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.01. On average, sell-side analysts predict that ALX Oncology will post -0.6 EPS for the current fiscal year.

ALX Oncology Company Profile

(Get Free Report)

ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.

The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.

Read More

• Five stocks we like better than ALX Oncology
• Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
• Kroger’s Textbook Entry for Buy-and-Hold Investors
• AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
• Amgen Drops 10% on a Trial It Didn’t Even Run

Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.